tumor involving the spleen, and is characterized by recurrent deletion of chromosome 7q and biased usage of the immunoglobulin heavy variable (IGHV) allele 1-2*04. 1 Genomic studies have partially unraveled the typical SMZL-coding genome, which is characterized by lesions affecting genes involved in the physiological homeostasis of marginal zone (MZ) B cells, including mutations of NOTCH2. [2] [3] [4] [5] However, the full spectrum of lesions that contribute to the malignant transformation of SMZL remains unknown.
In order to identify novel genetic lesions recurrently associated with SMZL, we extended mutation analysis to genes that, though known to be well-established regulators of MZ B-cell differentiation, had not emerged as significantly mutated from genomic studies of SMZL (Supplementary Tables S1 and S2). This analysis disclosed recurrent mutations of the Krüppel-like factor 2 (KLF2) zinc-finger gene, a transcription factor important for the homeostasis and differentiation of peripheral B-cell subsets, 6, 7 in 20% (19/96) of SMZL (Figure 1a ). To investigate the full complement of KLF2 mutations in the spectrum of lymphoid neoplasia, we extended the analysis to 547 mature B-and 113 T-cell tumors. In addition to SMZL, KLF2 mutations recurred also in 16% (4/24) of hairy cell leukemia, 11% (17/154) of diffuse large B-cell lymphoma (DLBCL), 9% (5/56) of nodal MZ lymphoma and 8% (5/61) of extranodal MZ lymphoma, whereas they were rare or absent (frequency = 0-4%) in the remaining entities ( Figure 1a ).
Overall, 80 KLF2 mutations were identified ( Supplementary  Table S3 ). Of these, 26% (n = 21) were truncating mutations (frameshift indels = 12; nonsense substitutions = 5; splice-site variants = 4) ( Figure 1b ). By complementary DNA analysis, splicesite mutations caused aberrant transcripts that retained intronic sequences and lost their coding potential. On the basis of their distribution along KLF2, truncating mutations were predicted to either disrupt the entire protein or to remove the zinc-finger (ZnF) domains of KLF2, including the putative nuclear localization signal (NLS) sequences ( Figure 1c ). [8] [9] [10] Missense mutations (n = 55) and in frame indels (n = 4) accounted for 74% of the variants (Figure 1b ). According to PolyPhen-2 (http://genetics.bwh.harvard. edu/pph2/), the majority of KLF2 missense substitutions were predicted to be deleterious ( Supplementary Table S3 ). A large fraction of the missense mutations (n = 27) clustered in the region encoding the first two ZnFs of KLF2, suggesting that they may affect its nuclear localization, as well as the transcriptional function of the protein (Figure 1c ). [8] [9] [10] [11] Notably, amino-acid changes recurrently affected evolutionarily conserved codons of the first ZnF, including recurrent substitutions at positions 288 (n = 9) and 291 (n = 5), which are involved in DNA recognition by KLF2 ( Supplementary Figure S1 ). 11 The 5′ basic NLS of KLF2, which maps before the ZnF, was also recurrently targeted by missense substitutions (n = 7) ( Figure 1c ). [8] [9] [10] [11] The remaining missense mutations distributed in the N-terminal activation domain (n = 7, including three somatic mutations targeting a hotspot at codon 37) and in the inhibitory domain (n = 14) ( Figure 1c ). 9,10 Targeted next generation sequencing analysis revealed that KLF2 mutations (assessable = 42) were clonally represented in the tumor (median variant allele frequency = 35%) ( Figure 1d ). Whenever possible, complementary DNA sequencing confirmed that KLF2 mutations (n = 21) were always expressed at the transcript level (Supplementary Figure S2 ). The somatic origin of mutations was confirmed in all tested cases by analysis of paired normal DNA, which was available for most of the variants (n = 52, including 36 missense substitutions) (Figure 1c ; Supplementary Table S3 ). Most (72%; 41/57) lymphoma cases harbored one single monoallelic KLF2 mutation. Among the cases displaying more than one mutational event, sequencing analysis of KLF2 transcripts after subcloning demonstrated that the mutations were generally (60%) located on separate alleles. Beside KLF2, no other KLF family member homologous to KLF2, nor genes belonging to the KLF2 pathway were mutated in SMZL ( Supplementary Table S1 ).
Copy number abnormalities of the KLF2 locus were examined by a combination of single nucleotide polymorphism array (n = 58 samples) and fluorescent in situ hybridization (n = 112 samples) in 96 SMZL and 74 DLBCL cases. Monoallelic KLF2 deletions occurred in 11% (11/96) SMZL and in 9% (7/74) DLBCL ( Supplementary  Table S4 ). One 174-kb focal loss of the KLF2 locus identified KLF2 as the specific target of the deletion (Supplementary Figure S3 ). KLF2 mutations and deletions were mutually exclusive in most samples, revealing a predominant monoallelic distribution (Supplementary Figure S3 ). Thus, when considering both mutations and copy number aberrations in cases, in which both types of alterations could be assessed, 31% (30/96) of SMZL and 26% (19/74) of DLBCL harbored KLF2 structural alterations (that is, mutations or deletions) (Supplementary Figure S3 ). In SMZL, KLF2 lesions were enriched among the cases harboring 7q deletion (61%, 11/18 vs 22%, 16/72; P = 0.0013), NOTCH2 mutations (55%, 10/18 vs 25%, 20/78; P = 0.013) and IGHV1-2*04 allele usage (47%, 10/21 vs 27%, 18/66; P = 0.082) (Supplementary Figure S4 ). In DLBCL, KLF2 lesions were restricted to cases showing a nongerminal center phenotype (Supplementary Figure S4) .
Cell lines and primary tumors carrying KLF2 heterozygous mutations retained expression of the unmutated allele at transcriptional (Supplementary Figure S2 ) and protein (Supplementary Figure S5 ) levels. Future experiments will be required to clarify whether KLF2 mutations act as a dominant negative or whether loss of one copy has functional impact. Western blot analysis, after fractionation of cytoplasmic and nuclear proteins, and confocal microscopy analysis were used to determine KLF2 distribution/localization across the subcellular compartments. In the SSK41 cell line, which harbors a wild-type gene, KLF2 was predominantly expressed in the nucleus (Figure 2a ). In contrast, the protein was primarily cytoplasmic (Figure 2a ) in cell lines harboring mutations that truncated or changed the amino-acid composition of the ZnFs, or targeted codons within or flanking the 5′ basic NLS of KLF2. Cytoplasmic KLF2 expression was also observed in primary tumor cells harboring a monoallelic KLF2 mutation of the ZnF (Figure 2a ). The near complete cytoplasmic expression of KLF2 observed in cases with monoallelic mutations warrants investigations aimed at testing whether wild-type KLF2 is sequestered by the mutant protein.
To provide a proof of principle of the functional significance of KLF2 mutations, we transfected human embryonic kidney 293T cells with flag-tagged wild-type KLF2 constructs and two mutants: (i) the p.P257* variant, representative of tumor cell mutations that truncate the C-terminal portion of KLF2, including its 5′ basic NLS sequence and the ZnFs; (ii) the p.H288Y variant, the most recurrent substitution affecting a hotspot codon Accepted article preview online 6 October 2014; advance online publication, 28 October 2014 0% 5% 10% 15% 20% 25% Mutation frequency 1 that is physiologically involved in DNA recognition by KLF2 and in its nuclear localization. [8] [9] [10] Confocal microscopy showed predominant nuclear localization of wild-type KLF2. In contrast, p. P257* and p.H288Y mutants were displaced from the nucleus (Figure 2b) . We then assessed the relative transactivation activity of the mutant KLF2 proteins by measuring their ability to upregulate the expression of a luciferase reporter gene driven by the CDKN1A/p21 promoter, a known direct target of KLF2, 12, 13 in human embryonic kidney 293T cells that lack endogenous KLF2 (Supplementary Figure S6) . Expression of wild-type KLF2, but not mutant, strongly induced the reporter (Figure 2c ), a finding consistent with the predicted loss of interaction between KLF2 mutants and DNA. KLF2 mutations represent one of the most frequent genomic abnormalities of SMZL, and unravel the disruption in human tumors of a previously unidentified molecular pathway. Given the involvement of KLF2 in the transcriptional regulation of an array of genes, it is difficult to predict which cellular targets/pathways may be critically affected by its mutations in lymphomagenesis. In normal lymphocytes, KLF2 binds the promoter and regulates the expression of genes involved in cell cycle/apoptosis (CDKN1A/p21) and cell trafficking (S1PR1, SELL/CD62L, ITGB7/β7-integrin and CXCR5). 6, 7, [12] [13] A limited set of KLF2 domains is necessary to exploit its transcriptional activities, including three highly conserved ZnFs, which allow protein contact with DNA, and two potent, independent NLS that mediate the localization of KLF2 in the nucleus. [8] [9] [10] [11] Consistent with the critical roles of the ZnFs and the NLS,~60% of KLF2 mutations disrupt or are predicted to modify these structures of the KLF2 protein. Our data confirm that KLF2 mutants lacking the NLS and some of those harboring missense substitutions of the first ZnF (codon 288 substitutions) are displaced from the nucleus and transcriptionally defective. Due to the large number of somatic missense KLF2 mutations disclosed by our molecular investigations, additional analyses are needed to comprehensively characterize the effects of the full spectrum of these variants. According to their distribution and predicted functional consequences, it is conceivable that, in addition to nuclear localization, missense substitutions might also disturb other KLF2 functions, including DNA binding, transcriptional activation or protein interactions.
As is the case for most cancer-associated genetic lesions, KLF2 inactivation may not be sufficient for malignant transformation. In fact, transgenic mice engineered to lack KLF2 in mature B cells display an expansion of the MZ at the expense of the follicular compartment, but do not develop lymphoma. 6, 7 It is important to note that, however, lymphoma development may require longer times than those observed so far in mice, 6, 7 in line with the indolent course of SMZL and the elderly age of patients affected by this lymphoma. Consistent with a multistep process of lymphomagenesis, KLF2 lesions frequently co-occur with IGHV1-2*04 usage, NOTCH2 mutations and 7q deletion in SMZL, suggesting a possible cooperation between genetic abnormalities and B-cell receptor configuration in promoting transformation.
Emerging evidence points to the role of KLF transcription factors in human cancers. 14 Although KLF family gene expression and function are altered in a large number of neoplasms, including B-cell tumors, recurrent structural alterations of these genes are exceedingly rare and sporadically restricted to solid cancers. 14, 15 Our data provide the first evidence of the molecular deregulation of KLF family genes in hematologic malignancies, and suggest that selection of KLF2 mutations has a role in transformation common to several lymphoma subtypes. Multiple myeloma remains a fatal haematological malignancy associated with clonal plasma cell expansion within the bone marrow, osteolytic bone disease, anaemia and renal failure. In almost all cases, myeloma is preceded by the nonmalignant plasma cell disorder monoclonal gammopathy of undetermined significance (MGUS), characterized by an increase in monoclonal immunoglobulin secretion, o10% plasma cells within the bone marrow and a lack of lytic bone lesions. The mechanisms underlying the pathogenesis of MGUS and progression to myeloma are complex with a major role attributed to the host microenvironment. A loss of host-derived adiponectin is known to promote myeloma development in vivo, both in murine models and in patients with MGUS. 1 Adiponectin is inversely linked to obesity, with increasing epidemiological evidence supporting an association between obesity and MGUS or myeloma. [2] [3] [4] [5] [6] [7] In the present study, we have combined a well-characterized murine model of myeloma with dietinduced obesity and a genetic model of obesity to determine the effect of increased obesity on myeloma development in vivo.
The Radl 5T myeloma model shares many of the clinical features seen in human myeloma and is widely used to study myeloma pathogenesis in vivo. 8 Myeloma is propagated by inoculation of 5T myeloma cells into the syngeneic C57BL/KaLwRij strain. However, myeloma does not develop when myeloma cells are inoculated into closely related C57BL6 mice, emphasizing the importance of the microenvironment in disease pathogenesis. 1 To determine the effect of diet-induced obesity on myeloma pathogenesis in vivo, we used a clinically relevant murine model where C57Bl6 mice were placed on a high-fat diet (42% fat) or control diet for 5 weeks, at which time a significant increase in body fat (Figure 1a ) and body weight ( Supplementary  Figure 1 ) was detected. Mice were then inoculated with 5TGM1 myeloma cells and the diet maintained for the duration of the experiment. C57BL6 mice on a high-fat diet before tumour inoculation developed features of myeloma including a significant increase in myeloma-specific IgG2 bκ paraprotein (Figure 1b ) and accumulation of green fluorescent protein (GFP)-positive myeloma cells in the bone marrow and spleen (Figure 1c ). MicroCT analysis of tibial trabecular bone volume revealed a trend towards a reduction in trabecular bone volume in myeloma-bearing mice on a high-fat diet (Figure 1d) , with subsequent experiments demonstrating significant bone loss in myeloma-bearing mice on a high-fat diet as compared with control ( Figure 1g ). It was notable that despite a significant accumulation of myeloma cells within the bone marrow and spleen in response to diet-induced obesity, the bone marrow was not completely replaced with tumour cells as is observed in 5T myeloma-bearing KaLwRij mice. 1, 8, 9 Indeed the features are more similar to MGUS, with an increase in paraprotein, accumulation of plasma cells within the bone marrow and mild bone loss. 10, 11 The combined assessment of tumour burden and bone loss revealed that 50% of mice on a high-fat diet exhibited both tumour growth within bone and bone loss, with a further 42% having detectable tumour, as compared with only 9% of mice on a control diet developing detectable tumour burden with no evidence of bone loss (Figure 1e) .
To determine the effect of withdrawal of the high-fat diet, in a separate experiment C57BL6 mice were placed on the high-fat diet or control. Two weeks post-tumour inoculation, following detection of an increase in serum paraprotein, mice were either removed from the high-fat diet and returned to the control diet, or remained on the high-fat diet for the duration of the experiment (Supplementary Figure 2) . Five weeks post-inoculation, all mice were sacrificed and tumour burden assessed. As before, C57BL6 mice inoculated with 5TGM1 cells and continuously fed a high-fat diet developed features of myeloma, whereas tumour-inoculated mice that were fed a control diet did not develop significant pathology (Figure 1f ). Removal of mice from the high-fat diet resulted in a reduction in tumour burden, but no change in trabecular bone volume, with the myeloma-induced trabecular bone defect suggestive of a delayed response to tumour regression (Figures 1f and g) . Combined, these in vivo data show that continuous diet-induced obesity promotes the establishment of an MGUS-like condition with associated bone loss, and that tumour burden is reduced upon removal of the diet, raising the possibility for effective dietary intervention strategies.
To determine whether diet-induced obesity created a permissive environment for myeloma in nonpermissive C57Bl6 mice, or whether the increase in body fat was merely promoting myeloma growth, myeloma-permissive KaLwRij mice were placed on the high-fat diet for 5 weeks before tumour-cell inoculation. 5TGM1 myeloma-cell inoculation resulted in tumour growth and osteolytic bone disease, however, despite a significant increase in body fat detected at time of tumour inoculation, no significant difference in serum paraprotein (Figure 2a ), tumour burden within bone marrow (control; 24.1 ± 2.9%, Accepted article preview online 7 October 2014; advance online publication, 31 October 2014
